lixisenatide glp 1 The European Commission Approves Sanofi and Zealand Pharma's GLP-1 Agonist Lyxumia (lixisenatide) CAS 320367 Peptide sequence of native human
Pay in 4 interest-free payments of $5.34 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15























